Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Ovarian Neoplasms 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 267Magnetic Resonance Spectroscopy 218pembrolizumab 203Carboplatin 170Cisplatin 137Biopsy 136Cyclophosphamide 131Paclitaxel 120Nivolumab 110Bevacizumab 104Gemcitabine 102Radiotherapy 85Dexamethasone 77Pemetrexed 75atezolizumab 73Fluorouracil 71fludarabine 69Doxorubicin 68Leucovorin 66Docetaxel 66Radiation 65Oxaliplatin 62Rituximab 60venetoclax 58Prednisone 58Cetuximab 54durvalumab 53Vincristine 52Etoposide 51130-nm albumin-bound paclitaxel 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
RC48 antibody × 30 days × Clear all
NCT06003231 2026-06-01

A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

Seagen Inc.

Phase 2 Active not recruiting
120 enrolled
GynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT07608224 2026-05-27

HOPE-07-MIBC

West China Hospital

Phase 2/3 Not yet recruiting
240 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡